Palbociclib, the first CDK4/6 inhibitor, was approved by the US Food and Drug Administration (FDA) as a therapeutic for estrogen receptor (ER)-positive metastatic breast cancer [10], and also exhibits pre-clinical efficacy in multiple cancers including NSCLC. Here, ESR1 is linked to non-small cell lung carcinoma.